393 results about "Mannitol" patented technology

Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

The invention belongs to the field of biology, and discloses a CRISPR / Cas12a freeze-dried microsphere, which is characterized in that the CRISPR / Cas12a freeze-dried microsphere is obtained by freeze-drying the following raw materials: enzyme-free water, 10 * HOLMES Buffer for Cas12a, an RNA enzyme inhibitor, CRISPR / Cas12a protein, crRNA, an upstream primer F, a downstream primer R, a fluorescent probe Reporter and a freeze-drying protective additive; the CRISPR / Cas12a protein is an LbaCas12a protein, and the CRISPR / Cas12a protein is a Cas12a protein; the freeze-drying protective agent is prepared from mannitol, trehalose, polyethylene glycol, glucan and BSA (Bovine Serum Albumin). By further optimizing a freeze-drying protective agent, freeze-drying microballing of a CRISPR / Cas12a system is achieved, the freeze-drying microballing can be matched with RPA constant-temperature amplification double microballing, and detection is conducted through a one-step method. Meanwhile, the invention further discloses a three-microsphere detection system, application and a kit.

The invention provides a battery and an electric device. A positive plate comprises a positive active material, and the positive active material is doped and / or coated with a lanthanum element; the surface of the diaphragm is coated with a ceramic coating; the electrolyte comprises a first solvent, a second solvent, a first additive and a second additive; the first solvent comprises a cyclic carbonate compound, the second solvent comprises a chain fluorosulfonamide compound, the first additive comprises mannitol carbonate sulfate, and the second additive comprises succinonitrile; the lanthanum element is doped / coated on the positive active material, so that the release of lattice oxygen at high voltage or high temperature can be effectively inhibited, and the exothermic reaction activity at the thermal runaway initial temperature is reduced; the first additive and the second additive in the electrolyte respectively form a compact CEI film and an SEI film with high thermal stability on the surfaces of the positive electrode and the negative electrode; the diaphragm ceramic coating provides a physical barrier, the thermal shrinkage temperature of the diaphragm is increased, and internal short circuit is prevented.

The invention discloses a low-temperature vacuum microwave freeze-dried sinomenine hydrochloride preparation and a preparation method thereof in the technical field of pharmaceutical preparations, and solves the problems of long drying time, high energy consumption and poor product stability in the traditional freeze-drying technology. A vacuum microwave collaborative freeze-drying technology is adopted, microwave internal heating is achieved through a 2.45 GHz magnetron microwave generator and a rectangular waveguide tube under the conditions that the vacuum degree is 20-30 Pa and the plate layer temperature ranges from-40 DEG C to-35 DEG C, the microwave power density in the primary drying stage ranges from 0.3 W / g to 0.5 W / g, the microwave power density in the secondary drying stage ranges from 0.1 W / g to 0.3 W / g, and collaborative control over the microwave power, the vacuum degree, the temperature and the time is achieved in cooperation with a quaternary coupling precise control system. The preparation contains 50 mg of sinomenine hydrochloride, 100 mg of mannitol and 10 mg of sodium carboxymethyl cellulose grafted modified polyvinylpyrrolidone, the residual moisture is controlled to be 0.4-0.6%, the activity retention rate is 94-96%, and the drying time is shortened to 12-16 hours.

The invention discloses a melatonin rapidly disintegrating oral tablet and a preparation method thereof, and the melatonin rapidly disintegrating oral tablet is prepared from the following raw materials in parts by weight: 40 to 55 parts of mannitol, 3 to 6 parts of cross-linked povidone, 0.5 to 2.0 parts of povidone, 2 to 6 parts of melatonin, 30 to 45 parts of filler and 0.3 to 1.5 parts of lubricant. Wherein the mannitol is beta-crystal form mannitol. According to the invention, mannitol of a limited type is matched with raw materials such as polyvinylpolypyrrolidone, and meanwhile, a specific mixing and tabletting process is adopted, so that the tablet can be rapidly disintegrated in an oral cavity while the hardness of the tablet is maintained, the bioavailability is high, and the requirements of the health food field on taking convenience, effectiveness and industrial production can be met.

Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.

The invention provides an anti-aging composition containing schizophyllan, a medical beauty injection preparation and application of the anti-aging composition and the medical beauty injection preparation, the anti-aging composition comprises hyaluronic acid or salt of the hyaluronic acid, the schizophyllan and mannitol, and the mass ratio of the hyaluronic acid or the salt of the hyaluronic acid to the schizophyllan to the mannitol is (0.2-3): (0.01-0.5): (0.5-5). According to the anti-aging composition disclosed by the invention, through the multi-component synergistic effect of the schizophyllatin, the hyaluronic acid or the salt thereof and the mannitol, the proliferation activity of fibroblasts can be remarkably improved, and the synthesis and expression of collagen can be efficiently promoted, so that the depth and the quantity of skin wrinkles are effectively improved, and the compactness and the elasticity of the skin are remarkably enhanced; the comprehensive skin rejuvenation effect is realized.

The invention provides a leavening agent and a preparation method thereof, and belongs to the technical field of leavening agents. According to the scheme, an efficient fermentation system is constructed through the synergistic effect of bacillus amyloliquefaciens, bacillus licheniformis, lactobacillus plantarum and saccharomyces cerevisiae, in the initial stage, the bacillus amyloliquefaciens secretes amylase and phytase degradation substrates, and conditions are created for the saccharomyces cerevisiae to metabolize monosaccharide to generate flavor substances and vitamins; in the middle stage, bacillus licheniformis decomposes protein to release amino acid, lactobacillus plantarum regulates pH through lactic acid metabolism to inhibit infectious microbes, and a multi-layer encapsulated compound enzyme preparation is introduced to synergistically degrade a complex substrate; in the later stage, fructooligosaccharide in the prebiotics-buffer stabilizer promotes proliferation of probiotics, mannitol and chitosan protect the activity of thalli and the function of metabolic enzymes, and the fermentation environment is stabilized; according to the whole system, the functionality, the environmental adaptability and the storage stability of the leavening agent are improved through flora synergistic metabolism, dynamic fermentation condition control and the action of the multifunctional additive, and the diversified requirements in industrial production are met.

The invention discloses preparation and application of a rabies virus G protein mRNA vaccine freeze-drying preparation, and relates to the field of veterinary biological products. According to the invention, rabies virus G protein mRNA is prepared on a large scale through an in-vitro transcription technology, and an mRNA-LNP (lipid nanoparticle) delivery system is successfully constructed by adopting a microfluidic encapsulation process. Through freeze-drying protective agent formula screening (including cane sugar, trehalose and mannitol) and freeze-drying procedure parameter optimization (including pre-freezing temperature, main drying rate and secondary drying residual moisture control), the freeze-dried mRNA vaccine preparation which can stably exist under the condition of 4 DEG C is finally obtained.

The invention provides a multilayer lutein ester liposome as well as a preparation method and application thereof, and belongs to the field of food processing. The multi-layer lutein ester liposome is prepared from the following raw materials: 30 to 50 parts of lutein ester, 40 to 60 parts of soybean phosphatidylcholine, 5 to 20 parts of cholesterol, 10 to 25 parts of starch sodium octenylsuccinate, 20 to 40 parts of trehalose, 15 to 30 parts of mannitol, 4 to 10 parts of phosphatidyl glycerol, 1 to 2 parts of vitamin E acetate and 1 to 2 parts of ascorbyl palmitate. According to the present invention, through the specific food-grade raw material composition and the accurate ratio relationship, the comprehensive delivery system is constructed for the highly hydrophobic and unstable lutein ester, and the system synchronously achieves the high encapsulation efficiency, the excellent stability, the good water dispersibility and the slow release function.

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention discloses afatinib tablets with high stability and rapid dissolution characteristics and a preparation method of the afatinib tablets, and belongs to the technical field of pharmaceutical preparations. In order to solve the problems that the dissolution rate is reduced and related substances are increased due to moisture absorption during the storage period of the existing afatinib tablets, afatinib dimaleate (crystal form A, D90 is 45-55m, and BET specific surface area is 2500-3000 m / kg) with a specific crystal form and particle size is adopted as a core and is compatible with an anhydrous crystal form auxiliary material (such as spray-dried mannitol), and the afatinib tablets are prepared into the afatinib tablets. Preparing a tablet core through dry granulation and a strict humidity control process, and then applying a damp-proof film coating. According to the scheme, the influence of water on the medicine is systematically blocked, the dissolution rate of the tablet in various dissolution media within 15 minutes is ensured to be greater than or equal to 85%, the dissolution rate is reduced by less than or equal to 5% after an accelerated test, the increase of related substances is obviously lower than that of a reference preparation, and the afatinib tablet with excellent dissolution performance and long-term stability is provided for clinic.

The application relates to the technical field of cough-relieving medicines, and discloses a high-efficiency cough-relieving loquat particle composition which is composed of the following components in parts by weight: loquat leaf extract 30-40 parts; white front extract 10-15 parts; platycodon grandiflorum extract 6-10 parts; white mulberry bark extract 18-25 parts; stemona sessiliflora extract 7-10 parts; menthol 0.1-0.5 part; polyethylene glycol 2-5 parts; mannitol 8-12 parts; ethyl cellulose 3-6 parts; hydroxypropyl methyl cellulose 1-3 parts; phosphatidylcholine 1-3 parts; polysorbate 80 1-3 parts; cross-linked sodium carboxymethyl cellulose 4-6 parts; and sucrose 40-60 parts. The double dispersion system combining the immediate-release component and the sustained-release component is adopted, the solubility and the initial release speed of the traditional Chinese medicine extract are remarkably improved through the addition of polyethylene glycol and mannitol, and the technical effect that the drug effect appearing time is remarkably shortened is achieved. Compared with the technical scheme relying on only a single release mode in the prior art, the deficiency that the drug effect is slow and the symptoms of the patient cannot be timely relieved is solved.

The invention discloses a pharmaceutical composition for improving liver dysfunction, the pharmaceutical composition comprises a tablet core and a coating film, the tablet core comprises 30-40 parts of mono-ammonium glycyrrhizinate (20-30 parts by weight of glycyrrhizin), 20-30 parts of glycine, 20-30 parts of methionine, 55-65 parts of a filler, 2-10 parts of a disintegrating agent, 1-10 parts of an adhesive and 1-10 parts of a lubricant, and the coating film is a gastric soluble film coating; wherein the filling agent is formed by compounding lactose, microcrystalline cellulose, calcium carbonate, calcium hydrophosphate and mannitol, the mass ratio of the lactose to the microcrystalline cellulose to the calcium carbonate to the calcium hydrophosphate to the mannitol is (1-24): (1-35): (1-25): (1-9): (1-9), and the pharmaceutical composition for improving liver dysfunction has good dissolution and stability.

The invention belongs to the technical field of high polymer material additives, and particularly relates to a multifunctional additive, a synthesis method thereof and application of the multifunctional additive in PVC (polyvinyl chloride) processing. Modified mannitol and binary acid are used as raw materials for esterification reaction to obtain a product A, the product A and yttrium salt are mixed for reaction to obtain a product B, and the product B and cinnamyl ethyl methacrylate are mixed for free radical reaction to obtain the multifunctional additive. The multifunctional auxiliary agent can be used as a heat stabilizer to improve the thermal decomposition temperature of PVC, can also be used as a light stabilizer to reduce the influence of illumination on PVC, and can be well applied to PVC processing.

The invention discloses a synthesis method of mannitol carbonate sulfate, and belongs to the technical field of organic synthesis. The synthesis method provided by the invention comprises the following steps: reacting 1, 3, 4, 6-tetrachloro-2, 5-hexanediol with chlorosulfonic acid in the presence of an acid-binding agent to obtain an intermediate solution as shown in a formula (II); formula (II); and mixing the intermediate solution as shown in the formula (II) with anhydrous carbonate, heating to a first set temperature for reaction, and then heating to a second set temperature for reaction in the presence of a phase transfer catalyst to obtain the mannitol carbonic sulfate. The whole process route is short, the yield is high, and the total yield of two steps reaches 88% or above; meanwhile, few by-products are generated, the purification difficulty is low, the reaction time is short, few hazardous wastes are generated, operation is easy and convenient, and industrial large-scale production is facilitated.

Intumescent composition comprising an acid donor (A), a carbon donor (B), a binder polymer (C) and a blowing agent (D). The acid donor (A) is selected from the group consisting of ammonium polyphosphate, ammonium dihydrogen phosphate, ethylenediamine phosphate, ammonium pentaborate, guanylurea phosphate, diguanidine phosphate and mixtures thereof. The carbon donor (B) is selected from the group consisting of glucose, arabinose and other monosaccharides, lactose, maltose and other disaccharides, starch, cellulose, dextrin and other polysaccharides, sorbitol, erythritol, pentaerythritol, dipentaerythritol, mannitol and other polyhydric alcohols and mixtures thereof. The blowing agent is provided in the form of microsphere particles comprising a thermoplastic polymer shell encapsulating a propellant, which microsphere particles are expandable microspheres.

The present application relates to a kind of toughened heat-resistant full biodegradable polylactic acid packaging material and its preparation method.Polylactic acid, PBAT, corn starch, stearic acid starch ester, mannitol, epoxy-terminated PBAT-PLA block oligomer, PDLA grafted white carbon black and processing aid are dried, premixed plasticized, melt reaction blending, extruded and granulated and formed, to obtain packaging material.Epoxy-terminated PBAT-PLA block oligomer improves interface compatibility and toughening, PDLA grafted white carbon black promotes crystallization and stereocomplex crystal formation, and both synergistically improve material toughness, impact resistance, heat resistance and hot water dimensional stability.

The present disclosure provides a method of reducing, preventing or treating an intestinal infection, preventing or treating a disease associated with protozoan parasite of the genus Eimeria, inhibiting an oocyst sporulation of a protozoan parasite or preventing a sporozoite invasion or reproduction, preventing or treating coccidiosis, promoting growth performance, controlling, treating and / or preventing necrotic enteritis in a subject, comprising administering to the subject an effective amount of a composition comprising a Crassocephalum rabens (CR), a bioactive extract thereof (CRE), an active ingredient(s) contained in a CR (CR_API) or CRE (CRE_API), a combination of two or more of a CR, a CRE, a CR_API and a CRE_API, or one or more of a-linolenic acid, citric acid, lactic acid, mannitol, palmitic acid, aspartic acid and 1-monomyristin.

The invention discloses a soluble microneedle composition for improving sleep and a microneedle and application of the soluble microneedle composition, and belongs to the technical field of medical care, the soluble microneedle composition comprises a needle tip section composition and a substrate composition, comprising 1%-70% of dexmedetomidine or a salt thereof, 1.5%-10% of glycerin, 1.5%-15% of mannitol and the balance of water. The substrate composition is an aqueous solution of a high-molecular compound. The soluble microneedle composition for improving sleep provided by the invention can prevent dexmedetomidine or a salt thereof from diffusing in a microneedle product, so that carried drugs are concentrated at a needle tip part, a technical support is provided for effective transmission of active components and accurate sustained and controlled release drug delivery, and quantitative drug delivery of dexmedetomidine or a salt thereof is realized.

The invention discloses an ophthalmic preparation and application thereof. The ophthalmic preparation comprises a TNF alpha nano antibody, a protective agent, a thickening agent, a buffer solution and an optional surfactant, and pH lt is larger than or equal to 6.0 and smaller than or equal to 0; 7, 7; the protective agent is selected from at least one of trehalose, mannitol, arginine and glycine; the thickening agent is selected from any one of hydroxypropyl methyl cellulose, polyvinyl alcohol and sodium hyaluronate; the buffer solution is a phosphate buffer solution or a histidine buffer solution. The ophthalmic formulations are useful in the treatment of immune-mediated inflammatory ophthalmic diseases.

Provided herein, according to an embodiment, is a nicotine-containing moist granulate composition comprising: nicotine or a pharmaceutically acceptable salt thereof; mannitol, and cellulose; the composition having a total moisture content of between 35-45%. The granulate shows favorable organoleptic qualities such as taste and mouthfeel and is free flowing to enable packaging in pouches. Optionally, the composition further comprises an oral health enhancing agent.

The invention discloses a preparation method of a levosimendan injection, and relates to the field of pharmaceutical preparations, the levosimendan injection is composed of a levosimendan solid preparation composition and a special dilution stabilizer; the solid preparation composition is prepared from active ingredients including levosimendan, povidone, a cosolvent and a stable protection additive, the stable protection additive is selected from one or more of mannitol, trehalose and glycine; the preparation method of the levosimendan injection comprises the following specific steps: firstly, forming a levosimendan povidone compound solution; then adding water for injection and fixing the volume to full dose; and drying to obtain the levosimendan solid preparation. A levosimendan solid preparation is matched with glucose or a sodium chloride solution, the levosimendan injection is obtained after uniform shaking, and the effect of improving the stability of the medicine is achieved by optimizing the adding mode, variety and physical state of the stable protection additive.

This invention discloses a phosphorylated diamine morpholino oligonucleotide drug that regulates PAPOLA expression and its application, belonging to the field of biomedical technology. The nucleotide sequence of the drug is shown in SEQ ID NO:1, targeting the coding region of human PAPOLA mRNA. The formulation is a lyophilized powder for injection, with excipients including mannitol and phosphate buffer. This invention also discloses the application of this drug in the preparation of a treatment for gastric cancer, specifically advanced gastric cancer with high PAPOLA expression. The drug is administered intravenously at a dose of 8-12 mg / kg every 3 days. Its mechanism of action is to block PAPOLA protein translation, inhibit the G1 / S phase transition of gastric cancer cells, and induce apoptosis. In vitro and in vivo experiments have confirmed that this drug can specifically inhibit the proliferation and growth of gastric cancer cells, providing a new treatment option for advanced gastric cancer.

The invention relates to the technical field of freeze-drying preparations, in particular to a plasma protective agent, a freeze-drying method for keeping the pH of plasma and freeze-dried plasma, and the plasma protective agent comprises the following components: an instant protective agent which comprises 5mg / ml of glycine; the feed additive is prepared from sodium dihydrogen phosphate, trehalose, hydroxyethyl starch, polyethylene glycol, mannitol, taurine, tryptophan lysine or glutamic acid. The sustained-release protective agent comprises antioxidant components encapsulated by lipidosome, wherein the antioxidant components comprise glutathione, adenosine and vitamin C. The invention also discloses a preparation method of the sustained-release protective agent. The novel protective agent vitamin C is adopted, the plasma pH adjusting operation is remarkably simplified, and the vitamin C is composed of multiple components with different functions, so that the stability of key components such as blood coagulation factors in plasma is greatly improved.

The application provides a method for improving the adenosine content of Ophiocordyceps sinensis based on metabolic regulation and synergistic induction, wherein a metabolic intervention is performed on the larva and strain complex using a regulating agent during the infection period before low-temperature treatment to form the infected larva; first, deep low-temperature immobilization treatment is performed at 2-5 DEG C for 30-50 days, then culture is performed using a variable-temperature cycle with diurnal temperature difference during the stroma induction period, and mannitol is sprayed onto the surface of the culture medium at the beginning of the step; after harvesting, rapid temperature rising enzyme inactivation and drying treatment is performed on the harvested Ophiocordyceps sinensis, the rapid temperature rising enzyme inactivation and drying treatment comprises increasing the drying temperature from 40-45 DEG C to 60-70 DEG C within 30-45 minutes and maintaining the temperature until the moisture content is less than 10%. The application can solve the problem that the adenosine content is generally low in the existing full artificial cultivation technology, and can make the adenosine content of the full artificial cultivation Ophiocordyceps sinensis reach more than 0.020% (w / v), which is significantly better than the existing artificial cultivation level, and the product morphology is complete and the reproducibility is high.

The application relates to a preparation method of an azilsartan solid dispersion and a medicinal composition thereof, and belongs to the technical field of pharmaceutical preparations. A unit dose of the azilsartan solid dispersion comprises azilsartan 20 mg, povidone K30 50-105 mg, sodium acetate trihydrate 4.9-5.7 mg, microcrystalline cellulose 210-270 mg, mannitol 65.6-83.2 mg, and sodium croscarmellose 8-24 mg which is added internally, and the preparation method is wet granulation; a unit dose of the azilsartan medicinal composition comprises the solid dispersion 429.5 mg, sodium croscarmellose 16 mg which is added externally, magnesium stearate 4.5 mg, and film coating premix 18 mg. The preparation process of the azilsartan solid dispersion is simple, almost all pharmaceutical factories have the hardware conditions, and no first and second class organic solvents are used, so that the safety and bioavailability of the azilsartan preparation are effectively improved; the stability of the azilsartan solid dispersion is good, and the dissolution rate and related substances do not obviously decrease after long-time storage.

The present invention discloses a composite biological deodorization filler, and relates to the technical field of deodorization fillers, the composite biological deodorization filler comprises a porous carrier, the surface of the porous carrier is coated with a slow-release coating, and the surface of the slow-release coating is compounded with a microbial flora; the slow-release coating consists of a mixture of trehalose and sodium glutamate, a mixture of betaine and mannitol and sodium carboxymethyl cellulose in a mass ratio of (6-9): (2-3): (4-6); the biofilm formation speed of the biological deodorization filler is increased, and the microbial activity attenuation speed is reduced; the invention further discloses a composite biological deodorization device which comprises a deodorization barrel, an air inlet pipe used for guiding in odor is arranged at the bottom of the deodorization barrel, an exhaust pipe is arranged at the top of the deodorization barrel, a filter frame is installed on a central rotating shaft in the deodorization barrel, and a middle core of the filter frame coincides with a shaft core of the central rotating shaft. The bottom frame surface of the filter frame is a conical surface with high periphery and low center; the phenomenon that the filler is accumulated on the frame is reduced, and the deodorization effect of the deodorization device is improved.

A sublingual tablet and application thereof in desensitization therapy drug are provided. The sublingual tablet is a low-dose allergen sublingual tablet. The sublingual tablet includes freeze-dried powder of allergen protein, lactose, mannitol, low substituted hydroxypropyl cellulose, low moisture microcrystalline cellulose, and magnesium stearate. The freeze-drying process is adopted to obtain the freeze-dried powder of allergen protein, and the powder direct compression technology is adopted to obtain the sublingual tablet of allergen protein. The low-dose sublingual tablet has excellent properties, including appearance, hardness, tablet weight variation, disintegration time, taste, and uniformity of content, in particular has outstanding advantages in disintegration time, uniformity of content, stability, and preparation process, and has an industrial application prospect.

The application discloses a freeze-drying protective agent for Streptococcus pneumoniae without animal source, and belongs to the field of microorganism preservation. The freeze-drying protective agent is composed of the following components: 1-5% (weight / volume) soybean peptone, 1-5% (weight / volume) trehalose, 4-8% (weight / volume) mannitol and 0.3-1.5% (volume / volume) glycerol, and the rest is water. The freeze-drying protective agent can better maintain the activity of Streptococcus pneumoniae, and the effect is equivalent to that of a skimmed milk protective agent or a commercially available freeze-drying protective agent without animal source, but the freeze-drying protective agent does not contain animal source components and has low cost.